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ABSTRACT
Triple-negative breast cancer (TNBC) represents approximately 10–17% of all 
breast cancers, and patients with TNBC show a poorer short-term prognosis than 
patients with other types of breast cancer. TNBCs also have a higher tendency for 
early distant metastasis and cancer recurrence due to induction of the epithelial-
mesenchymal transition (EMT). Several recent reports have suggested that inhibitor 
of apoptosis (IAP) proteins function as regulators of the EMT. However, the roles 
of these proteins in TNBC are not clear. Accordingly, we investigated the roles of 
cIAP2 in TNBC. Among eight IAP genes, only cIAP2 was upregulated in TNBC cells 
compared with that in other breast cancer subtypes. Analysis of TMAs revealed that 
expression of cIAP2 was upregulated in TNBCs. In vitro studies showed that cIAP2 
was highly expressed in TNBC cells compared with that in other types of breast cancer 
cells. Furthermore, silencing of cIAP2 in TNBC cells induced mesenchymal-epithelial 
transition (MET)-like processes and subsequently suppressed the migratory ability 
and invasion capacity of the cells by regulation of Snail through the AKT signaling 
pathway. In contrast, ectopic expression of cIAP2 in luminal-type breast cancer cells 
induced activation of the AKT signaling pathway. These results collectively indicated 
that cIAP2 regulated the EMT in TNBC via activation of the AKT signaling pathway, 
contributing to metastasis in TNBC. Our study proposes a novel mechanism through 
which cIAP2 regulates the EMT involving AKT signaling in TNBC cells. We suggest 
that cIAP2 may be an attractive candidate molecule for the development of targeted 
therapeutics in the future.
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INTRODUCTION
Breast cancer is currently one of the most common 
cancers. Worldwide, approximately 22% of new cancers 
are diagnosed as breast cancer, and the number of patients 
with breast cancer has reached about 3.9 million. In 
women, breast cancer is a leading cause of mortality, with 
approximately 520,000 annual deaths [1]. With the recent 
success of therapy based on molecular targeted drugs 
against breast cancer [2], further improvements in the 
efficacy of anticancer treatments are expected. However, 
there are no cure-all cancer therapies. Many types of breast 
cancers do not respond to current treatments, making the 
effective treatment of cancer difficult.
Clinically, breast cancer is usually categorized based 
on the expression of specific receptors, including estrogen 
receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2)/neu (also 
known as ERBB2). Cancers expressing none of these three 
receptors are referred to as triple-negative breast cancers 
(TNBCs), which account for 10–17% of all breast cancers 
[3]. TNBCs show a relatively poorer prognosis compared 
with other types of breast cancer and often cannot be 
subjected to current targeted therapies due to the absence 
of receptors, which can act as therapeutic target molecules. 
Additionally, TNBCs are known to be associated with a 
higher tendency of progression to metastatic diseases, 
the major cause of breast cancer-related death [4]. The 
lack of efficient targeted therapy and higher potential for 
metastatic progression of TNBCs need to be overcome in 
order to improve breast cancer therapies. To conquer breast 
cancer, novel strategies based on molecular mechanisms 
associated with TNBC will be necessary.
Cancer metastasis is a multicellular process 
involving a series of steps from primary cancer to 
metastatic malignancy at distal sites. During metastasis, 
cancer cells in primary tumors must change from the 
epithelial phenotype to the mesenchymal phenotype in 
order to penetrate into the basement membrane, a process 
called the epithelial-mesenchymal transition (EMT) 
[5]. Many studies have shown that transcription factors, 
including Snail/Slug, Twist, and Zeb family proteins, 
govern the overall EMT process by regulation of various 
structural and adhesion/junction molecules [6]. Because 
the EMT is a key contributor to the metastatic process, 
its regulatory mechanisms should be well organized and 
controlled. Although various transcription factors and their 
target genes have been extensively studied in the EMT 
processes, signaling molecules associated with the EMT 
are relatively poorly understood. Recently, several studies 
have reported novel molecules with EMT regulatory 
functions [7-9].
Inhibitor of apoptosis proteins (IAPs), also known 
as baculovirus IAP repeat (BIR) domain-containing 
proteins (BIRCs), are a protein family including eight 
proteins commonly possessing BIR domains, including 
BIRC1 (NAIP), BIRC2 (cIAP1), BIRC3 (cIAP2), BIRC4 
(XIAP), BIRC5 (Survivin), BIRC6 (BRUCE), BIRC7 
(Livin), and BIRC8 (ILP2) [10]. IAPs many function as 
E3 ligases owing to their C-terminal RING domains and 
are able to degrade proteins by linking them to ubiquitin 
molecules [11]. Because XIAP, cIAP1, and cIAP2 are 
directly or indirectly related to the apoptosis pathway 
through inhibition of caspases, many drugs for cancer 
therapy have focused on inhibition of IAPs [12].
Recently, several reports have suggested the 
possibility of another function of IAPs as regulators of 
the EMT [13]. However, the function of IAPs related to 
the EMT process and cancer metastasis is still unclear. 
XIAP and cIAP2 are thought to be positive regulators 
of the EMT [14-16]. In contrast, one study showed that 
XIAP and cIAP1 inhibit the EMT by inducing Rac1 
degradation [17]. Thus, because of the inconsistencies 
in clinical analysis of IAPs in cancer prognosis, further 
analyses are needed to determine the roles of IAPs in 
cancer progression and metastasis.
In this study, we evaluated the expression patterns of 
IAPs in several breast cancer cell lines. Subsequently, we 
examined the role of cIAP2 in TNBC and the EMT. Our 
findings provided important insights into the mechanisms 
through which cIAP2 modulates the EMT in TNBC.
RESULTS
cIAP2 was highly expressed in TNBC
To investigate the relevance of IAP expression in 
TNBC, we assessed mRNA expression levels for all 
IAP members in luminal-type (T-47D, BT474, MCF7), 
HER2-positive-type (SK-BR-3), and triple-negative 
(MDA-MB-231 and Hs 578T) breast cancer cell lines 
(Supplementary Table 1) [18-20]. Among the eight IAP 
genes evaluated in this study (BIRC1–8), only cIAP2 
(BIRC3) was highly expressed in TNBC cells compared 
with that in other breast cancer subtypes, while other IAP 
members were detected in various breast cancer cells, 
irrespective of their subtypes (Figure 1).
To determine the expression level of cIAP2 in breast 
cancers tissues, we performed TMA analysis using IHC 
staining. When classified according to the degree of cIAP2 
expression (Figure 2 and Supplementary Table 2), about 
96% of patients with TNBC showed positive expression 
of cIAP2 in cancer tissues, whereas only 4% of TNBC 
tissues showed no cIAP2 expression (Table 1), suggesting 
that cIAP2 may play a role in TNBC.
cIAP2 expression was related to EMT-associated 
gene expression
To confirm the molecular meaning of the TMA 
results, we next assessed mRNA and protein levels of 
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cIAP2 in luminal-type breast cancer cell lines (BT474 and 
MCF7; non-TNBC) and TNBC cell lines (MDA-MB-231 
and Hs 578T). In accordance with IHC analysis of breast 
cancer TMA in Table 1, cIAP2 was highly expressed in 
TNBC cell lines but barely detected in luminal-type cell 
lines at both the protein (Figure 3A and 3B) and mRNA 
(Figure 3C and 3D) levels.
Our data for TMA, qPCR, and IHC analyses showed 
strong correlations between cIAP2 expression and TNBC. 
Thus, we hypothesized that cIAP2 may play important 
Figure 1: Analysis of IAP expression in breast cancer cells. mRNA expression of IAPs was examined in luminal-type breast 
cancer cells (T-47D, BT474, MCF7), HER2-positive breast cancer cells (SK-BR-3), and triple-negative breast cancer cells (MDA-MB-231, 
Hs 578T).
Figure 2: Immunohistochemical analysis of cIAP2 in triple-negative breast cancer tissues. Expression of cIAP2 in triple-
negative breast cancer tissue was evaluated in high-power fields (200×). (A) Negative for cIAP2. (B) 1+ for cIAP2. (C) 2+ for cIAP2. 
cIAP2 was generally observed in the cytoplasm in triple-negative breast cancer tissue.
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Table 1: Comparison of cIAP2 expression in triple-negative breast cancer tissue microarrays using 
immunohistochemistry (IHC)
Interpretation TNBC TMA (N=100)
Quick score Frequency Percent
Negative (0) 0 4 4%
1 0
2 0
Weak/Moderate (1+) 3 20 52%
4 13
5 19
Strong (2+) 6 38 44%
7 6
8 0
The cIAP2-positive status was assigned for scores “1+” and “2+.”
Figure 3: cIAP2 expression in breast cancer cell lines. Expression of cIAP2 was examined on luminal-type (BT474, MCF7) and 
triple-negative (MDA-MB-231, Hs 578T) breast cancer cells. (A) Western blotting was performed to determine the protein expression level 
of cIAP2. β-Actin was used as a loading control. (B) Graphical representation of western blot band intensities quantified using Image J (n = 
3). Expression of cIAP2 mRNA was examined by (C) RT-PCR and (D) quantitative real-time PCR. For quantification of the results in (B) 
and (D), the cIAP2 protein and mRNA level for BT474 cells was set to 1. Values represent the means ± standard deviations.
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roles in regulating the clinical features of TNBCs, 
including poor prognosis and high metastatic tendency. 
Therefore, we investigated the possibility that cIAP2 may 
regulate the metastatic characteristics of breast cancers by 
detection of epithelial/mesenchymal markers known to 
be closely related to metastatic progression. At both the 
protein and mRNA levels, epithelial markers were detected 
in luminal-type cell lines; in contrast, mesenchymal 
markers were primarily expressed in TNBC cell lines 
(Figure 4A and 4B). Next, wound healing assays were 
performed to determine the effects of cIAP2 expression 
on the metastatic phenotype. The results showed far higher 
migration capacity in TNBC cell lines compare with that 
in luminal-type cell lines (Supplementary Figure 1).
Based on epithelial/mesenchymal marker 
expression patterns and migratory capacity (Figure 4 
and Supplementary Figure 1), we speculated that cIAP2 
may function as a regulator of the EMT. To verify this, 
we evaluated changes in epithelial and mesenchymal 
markers after silencing of cIAP2 mRNA in TNBC cell 
lines. Notably, all of the mesenchymal markers we tested 
were reduced by cIAP2 knockdown at both the protein 
and mRNA levels (Figure 5A-5C). In contrast, mRNA of 
epithelial markers, including CDH1 (encoding E-cadherin) 
and EPCAM (encoding EpCAM) were obviously increased 
in cIAP2-knockdown cells (Figure 5C and 5D). These 
changes in mesenchymal to epithelial markers by cIAP2 
knockdown indicated that cIAP2 was a positive regulator 
of the EMT process.
cIAP2 knockdown suppressed cell migration and 
invasion in breast cancer cell lines
During the EMT process, changes in epithelial/
mesenchymal features of cells lead to migration and 
invasion, which are essential for cancer metastasis [21]. 
Thus, we assessed the migration and invasion capacities of 
cIAP2-knockdown TNBC cells. In wound healing assays, 
control MDA-MB-231 and Hs 578T cells showed high 
migratory capacity, consistent with the results shown in 
Supplementary Figure 1; however, significantly attenuated 
cell migration was observed in both cell lines with cIAP2 
knockdown (Figure 6A and 6B). The wounds were then 
filled with Matrigel to mimic the extracellular matrix in 
order to assess invasiveness. Our analysis showed that 
invasiveness was greatly inhibited in cIAP2-knockdown 
Figure 4: Comparison of cIAP2 expression and EMT-associated molecules in breast cancer cells. Expression of cIAP2 and 
EMT-associated molecules were examined in luminal-type (BT474, MCF7) and triple-negative (MDA-MB-231, Hs 578T) breast cancer 
cells at (A) protein and (B) mRNA levels. β-Actin and GAPDH were used as loading controls.
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cells (Figure 6C and 6D). Thus, cIAP2 played critical roles 
in determining the cell migration and invasion capacity in 
TNBC cells.
One of the molecular functions of cIAP2 is 
inhibition of cell death [11], which may affect cell 
migration and invasion. However, among IAPs, the 
major inhibitory molecule of apoptosis is thought to be 
XIAP, and cIAP2 may have a relatively minor role in 
the regulation of apoptosis, despite its binding affinity 
to caspase [22, 23]. To exclude the effects of cIAP2 on 
cell death in our measurement of cell migration and 
invasion, we also evaluated cell proliferation after cIAP2 
knockdown; no significant difference was observed 
between si-scramble- and si-cIAP2-transfected cells 
Figure 5: Analysis of EMT-associated molecules in TNBC cells (MDA-MB-231 and Hs 578T) with cIAP2 silencing. 
(A) Expression of EMT-associated mesenchymal markers, including N-cadherin, vimentin, α-SMA, Snail, and Slug, was determined at 
the protein level in MDA-MB-231 and Hs 578T cells transfected with si-cIAP2. β-Actin was used as a loading control. (B) Graphical 
representation of western blot band intensities quantified using Image J (n = 3). (C and D) Expression of EMT-associated markers, including 
CDH1, EPCAM, ACTA2, Vim, SNAI1, and SNAI2, was determined at the mRNA level in MDA-MB-231 and Hs 578T cells transfected with 
si-cIAP2 by (C) RT-PCR and (D) quantitative real-time PCR. Values represent the means ± standard deviations.
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(Supplementary Figure 2). Thus, the reduced migratory/
invasive capacity of cIAP2-knockdown cells was assumed 
to be mostly due to inhibition of the EMT.
The AKT signaling pathway was related to 
cIAP2-mediated induction of the EMT
Next, we attempted to investigate the molecular 
mechanisms of cIAP2-mediated EMT induction. Several 
signaling pathways related to the EMT process were 
evaluated (data not shown), and we found that the AKT 
signaling pathway was significantly altered following 
cIAP2 manipulation (Figure 7). In previous reports, the 
AKT signaling pathway was shown to induce the EMT 
process through inhibitory phosphorylation of GSK3β, a 
negative regulator of the EMT-related transcription factor 
Snail [24, 25]. Thus, we then evaluated the expression 
of AKT-associated signaling molecules in cIAP2-
knockdown TNBC cells. Western blot analysis showed 
that phosphorylation of AKT was attenuated by silencing 
Figure 6: Silencing of cIAP2 suppressed the migration and invasion ability of TNBC cells (MDA-MB-231 and Hs 
578T). (A) Migration of MDA-MB-231 (si-control and si-cIAP2) and Hs 578T (si-control and si-cIAP2) cells was examined by wound 
healing assay. (C) Invasion capacity of MDA-MB-231 (si-control and si-cIAP2) and Hs 578T (si-control and si-cIAP2) cells was examined 
by scratch wound invasion assay. The wound gap was photographed every 6 h. The initial wound width was 700 μm (10× magnification). 
(B and D) Wound closure (%) was measured using IncuCyte ZOOM software (n = 5). Values represent the means ± standard deviations. 
*P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 7: cIAP2 promoted the EMT through the AKT signaling pathway. The expression of AKT signaling pathway-associated 
molecules was analyzed in (A) cIAP2-silenced TNBC cells and (B) luminal-type breast cancer cells ectopically expressing cIAP2. β-Actin 
was used as a loading control. (C) Proposed model for the molecular mechanisms through which cIAP2 induced the EMT. The bold lines 
represented an effect that was reinforced by cIAP2, whereas the dotted lines represented an effect that was weakened by cIAP2.
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of cIAP2, leading to reduced phosphorylation of GSK3β 
and subsequent destabilization of Snail (Figure 7A). 
As a consequence of reduced GSK3β phosphorylation, 
we observed reduced expression of Snail at the protein 
level (Figure 5A and 5B). Additionally, we analyzed 
the expression of AKT-associated signaling molecules 
in cIAP2-transfected MCF7 and BT474 cells. Western 
blot analysis showed that phosphorylation of AKT 
was increased by ectopic expression of cIAP2, leading 
to increased GSK3β phosphorylation and subsequent 
stabilization of Snail protein (Figure 7B).
Interestingly, SNAI1 expression was also decreased 
by silencing of cIAP2 (Figure 5C and 5D). Nuclear factor 
kappa B (NF-κB) is a well-known transactivator of SNAI1 
[26] and a target of AKT regulation [27]. Therefore, we 
next evaluated the phosphorylation of IκBα, which acts as 
an inhibitor of NF-κB activation. In western blot analysis, 
we found reduced phosphorylation of IκBα by silencing of 
cIAP2 (Figure 7A).
Thus, our data collectively suggested that cIAP2 
induced the EMT through activation of both AKT/GSK3β 
and AKT/NF-κB signaling pathways (Figure 7C).
DISCUSSION
IAPs are proto-oncogenes involved in the regulation 
of tumor progression, metastasis, cell survival, and 
migration. In particular, cIAP2 is upregulated in colorectal 
cancer, mucosa associated lymphoid tissue lymphoma, 
acute myeloid leukemia, and lung cancer and is associated 
with poor tumor prognosis [10]. However, no reports have 
described the clinical significance of cIAP2 in breast 
cancers.
Although cIAP2 has been reported to be upregulated 
in several types of cancer, the roles of IAPs in the EMT 
are still unclear [14, 15, 17, 28, 29]. IAPs share high 
homology and show functional redundancy; however, 
each IAP may induce different effects in EMT regulation. 
In the current study, our findings supported that cIAP2 
functioned as a positive regulator of the EMT in TNBC. 
Despite these findings, it is still unclear whether other 
IAPs also promote the EMT process, although their 
expression levels did not differ among cell lines showing 
low and high migratory capacity.
In this study, we verified that cIAP2, which was 
upregulated in TNBC compared with other breast cancer 
subtypes, induced the EMT in TNBC cells via activation 
of the AKT signaling pathway. Several reports of IAP-
mediated EMT induction have shown that this mechanism 
involves the regulation of small Rho GTPases [14, 16, 17, 
30, 31]. Gradients of Rho GTPase proteins are associated 
with cell polarity and mobility, which are critical factors 
involved in the EMT process [32]. Because the EMT 
process involves various cellular changes, adjustment 
of major transcription factors, such as Snail, Twist, and 
Zeb family proteins, is also necessary. Accordingly, AKT 
signaling and Snail regulation by cIAP2 could be the main 
mechanism mediating the EMT process.
Dysregulation of AKT signaling in breast cancer 
has been extensively reported in previous studies. The 
activating mutation of PIK3CA is frequently observed in 
breast cancers, particularly luminal-type cancer, which 
leads to hyperactivation of the AKT signaling pathway [33-
35]. The luminal-type breast cancer cell lines used in our 
study (MCF7 and BT474 cells) had mutations in PIK3CA 
[19, 36], whereas TNBC cell lines (MDA-MB-231 and 
Hs 578T cells) had wild-type PIK3CA. In our experiment, 
BT474 cells showed highly activated AKT signaling despite 
weak expression of cIAP2 (data not shown); this could 
be explained by the presence of mutated PIK3CA. In the 
case of MCF7 cells, relatively low levels of phospho-AKT 
were detected (data not shown), consistent with previous 
studies showing that some luminal-type breast cancer cell 
lines, such as MCF7 cells, show weak activation of AKT 
signaling despite PIK3CA mutations; the authors speculated 
that this effect may be related to the function of another 
AKT regulator. Notably, in our study, cIAP2 was expressed 
only in TNBC, and luminal-type breast cancer was negative 
for cIAP2. Therefore, cIAP2 may be responsible for the 
induction of AKT signaling in TNBCs, whereas AKT 
activation in luminal-type breast cancer was mainly affected 
by the status of PIK3CA and other factors, independent of 
cIAP2 expression.
The AKT signaling pathway has been shown 
to positively influence EMT progression [37]. The 
mechanisms of AKT-mediated EMT induction can 
be summarized as follows. First, activated AKT 
phosphorylates GSK3β (inhibitory phosphorylation) 
and subsequently prohibits the phosphorylation of Snail, 
leading to its degradation [25]. Second, activated AKT 
can also phosphorylate and activate IKK, which triggers 
nuclear localization of NF-κB. Then, NF-κB activates the 
transcription of SNAI1 [38]. Consistent with these findings, 
we observed reduced Snail expression at both the protein 
and mRNA level, following cIAP2 knockdown, suggesting 
that cIAP2 induced the EMT by both transcriptional and 
post-translational regulation of Snail through induction of 
AKT signaling.
Slug is another transcription factor with important 
roles in the EMT process [39]. In this study, we observed 
changes in SNAI2 (Slug) as well as SNAI1 (Snail) at both 
the mRNA and protein levels after cIAP2 manipulation, 
suggesting the possibility of Slug regulation by AKT 
signaling, similar to the mechanism described for Snail 
regulation. Indeed, post-translational regulation of Slug 
by AKT/GSK3β signaling has recently been described 
[39]. Additionally, some reports have shown that Slug 
is regulated by the NF-κB signaling pathway [40, 41]. 
However, the roles of AKT in regulation of SNAI2 have 
not yet been clarified. Further studies are needed to better 
establish the roles of the AKT signaling pathway in the 
EMT process.
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The NF-κB signaling pathway is involved in 
many biological processes, including cell proliferation, 
cell differentiation, immune responses, and apoptosis, 
and the dysregulation of NF-κB is involved in many 
diseases, including inflammatory/autoimmune disease, 
tissue malformation, and tumorigenesis [42]. cIAP1 and 
cIAP2 have been reported to be essential for NF-κB signal 
transduction via K63-linked ubiquitination of RIP1 [11, 
12]. At the same time, cIAP1 and cIAP2 are also targets 
of NF-κB-transactivation, suggesting the involvement 
of positive feedback in the regulation of cIAP1/2 
expression [43]. As shown in our study, cIAP2 activated 
AKT signaling, supporting the involvement of another 
feedback loop in the regulation of cIAP1/2 expression as 
AKT signaling can also activate NF-κB. Although more 
in-depth studies are required, our results provided insights 
into a novel signaling pathway and could improve our 
understanding of NF-κB signal transduction.
We observed a clear, significant effect of cIAP2 
knockdown on the EMT process in cIAP2-positive TNBC 
cell lines. However, ectopic expression of cIAP2 in breast 
cancer cell lines, which rarely expressed cIAP2, did not 
show meaningful changes in the EMT process, except 
activation of the AKT signaling pathway. This may due to 
the masking effect of ER and/or PR in breast cancer cells. 
Consistent with our study, most cIAP2-negative breast 
cancer cell lines are luminal type (expressing ER and/or 
PR), and some reports have suggested that ER and/or PR 
repress EMT progression [44-51], although these findings 
are controversial [52-55]. In accordance with this, it is 
possible that EMT progression is eventually prohibited by 
ER and/or PR signaling in cIAP2-negative breast cancer 
cells, despite ectopic expression of cIAP2. To determine 
the exact mechanisms mediating this process, more in-
depth studies are required.
Recently, several small molecule inhibitors of IAPs 
(including diablo IAP-binding mitochondrial protein-
mimicking molecules [SMAC mimetics]) have been 
developed, some of which have entered phase II trials 
as potential cancer therapies [56]. The major evidence 
supporting the use of SMAC mimetics is induction of 
apoptosis by inhibition of IAPs, which can drive cancer 
cell death. Thus, based on our findings, it is possible that 
SMAC mimetics also attenuate EMT progression via 
inhibition of cIAP2, eventually acting to block cancer 
metastasis. Therefore, SMAC mimetics, as therapeutics 
for both cell death induction and EMT inhibition, may be 
novel candidates for the treatment of TNBC.
Our current findings revealed that cIAP2 was 
highly expressed in TNBC compared with other types 
of breast cancer, both in vivo and in vitro. Additionally, 
we found that cIAP2 regulated the EMT via the AKT 
signaling pathway. Our data suggested that cIAP2 could 
be an attractive candidate for development of targeted 
therapeutics and a potential diagnostic marker for 
predicting tumor metastasis.
MATERIALS AND METHODS
Cell culture
Human breast cancer cell lines, including T-47D, 
BT474, MCF7, SK-BR-3, MDA-MB-231, and Hs 578T 
cells, were purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA) and grown in 
accordance with ATCC recommendations. Cell culture 
medium was supplemented with 10% heat-inactivated fetal 
bovine serum (FBS; Hyclone, Logan, UT, USA) and 10 
U/mL penicillin-streptomycin (Hyclone). The cells were 
cultivated at 37°C in a humidified atmosphere containing 
5% CO2.Characteristics of the breast cancer cell lines 
used in this study are described in Supplementary Table 
1. All cell lines used in this study were authenticated by 
short tandem repeat profiling at the Research Institute of 
National Cancer Center (Goyang, Gyeonggi-do, Republic 
of Korea).
Construction of cIAP2-siRNA and cIAP2 
expression vector
For knockdown of cIAP2 (NM_001165) mRNA, the 
following sequences were used: si-cIAP2, 5′-GGAGAGA
AUUAUAGACUAGUCAATG-3′; si-Control (nonspecific 
oligo), 5′-CGUUAAUCGCGUAUAAUACGCGUA-3′ 
(IDT, Coralville, IA, USA). MDA-MB-231 and Hs 578T 
cells were transfected with cIAP2-siRNA or control-
siRNA at 50% cell confluence using Lipofectamine 
RNAi MAX (Invitrogen, Green Island, NY, USA) 
according to the manufacturer’s instructions. The optimal 
concentrations of siRNA for gene silencing were 50 nM 
for MDA-MB-231 cells and 25 nM for Hs 578T cells.
For ectopic expression of cIAP2, the pRK5-Flag-
cIAP2 plasmid construct was purchased from Addgene 
(Cambridge, MA, USA). The pRK5-Flag vector was used 
as a control. The plasmids were transfected into breast 
cancer cells using Lipofectamine 2000 (Invitrogen), 
according to the manufacturer’s instructions.
Cell proliferation assay
Cell proliferation rates were measured using 
a Cell Counting Kit-8 (CCK-8; Dojindo Molecular 
Technologies, Inc., Rockville, MD, USA) according to 
the manufacturer’s instructions. Briefly, cIAP2-silenced 
TNBC cells were plated in 96-well microplates at a 
density of 3 × 103 cells/well for MDA-MB-231 cells 
and 1 × 103 cells/well for Hs 578T cells. Next, 10 μL 
CCK-8 solution (2-[2-methoxy-4-nitrophenyl]-3-[4-
nitrophenyl]-5-[2, 4-disulfophenyl]-2H-tetrazolium) was 
added to each well. The plates were incubated at 37°C in 
an incubator for 3 h, and the absorbance at 450 nm was 
measured using an Epoch Microplate Spectrophotometer 
(BioTek Instruments, Inc., Winooski, VT, USA).
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Western blot analysis
Cell lysates were prepared in RIPA buffer (50 
mM Tris-Cl [pH 7.5], 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulfate 
[SDS]) supplemented with protease inhibitors. The protein 
concentration was determined using a BCA assay kit 
(Thermo Fisher, Waltham, MA, USA). Whole-cell extracts 
were boiled in 4× SDS sample buffer (2% SDS, 50 mM 
Tris-HCl [pH 6.8], 0.4 mM ethylenediaminetetraacetic 
acid [EDTA, pH 8.5], 10% glycerol, 0.002% pyronin Y) 
supplemented with 2-mercaptoethanol. The denatured 
protein was separated by SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) on 10% gels and transferred 
to 0.45-μm nitrocellulose membranes (Bio-Rad, Hercules, 
CA, USA) by semidry transfer. The membranes were 
washed with Tris-buffered saline containing 0.05% Tween 
20 (TBS-T) and blocked for 1 h in TBS-T containing 
5% skim milk. The membranes were then incubated 
with primary antibodies diluted with TBS-T at 4°C 
overnight and then washed three times with TBS-T. The 
membranes were incubated with horseradish peroxidase 
(HRP)-conjugated secondary antibodies diluted in 
TBS-T containing 5% skim milk at room temperature 
for 90 min, followed by five washes with TBS-T. Finally, 
protein bands were visualized using WesternBright ECL 
Chemiluminescent HRP Substrate (Advansta, Menlo Park, 
CA, USA).
Primary antibodies were as follows: anti-cIAP2 
(#3130; Cell Signaling Technology, Danvers, MA, USA), 
anti-E-cadherin (610181; BD Biosciences, Sparks, MD, 
USA), anti-epithelial cell adhesion molecule (EpCAM; 
ab71916; Abcam, Milton, Cambridge, UK), anti-N-
cadherin (33-3900; Invitrogen), anti-α-smooth muscle 
actin (SMA; RB-9010-P; Invitrogen), anti-vimentin 
(M0725; Dako, Glostrup, Denmark), anti-Slug (#9585; 
Cell Signaling Technology), anti-Snail (#3895; Cell 
Signaling Technology), anti-phospho-AKT (Ser473; 
#4058; Cell Signaling Technology), anti-total AKT 
(#4691; Cell Signaling Technology), anti-phospho-
glycogen synthase kinase (GSK) 3β (Ser9; #5558; 
Cell Signaling Technology), anti-GSK3β (#9315; 
Cell Signaling Technology), anti-phospho-inhibitor 
of kappa B alpha (IκBα; Ser32; #2859; Cell Signaling 
Technology), anti-IκBα (#9242; Cell Signaling 
Technology), anti-β-actin (AC-15; Sigma Aldrich, St. 
Louis, MO, USA).
Immunohistochemical (IHC) staining
TNBC tissue microarray (TMA) slides (100 cases) 
were obtained from Gangnam Severance Hospital (Yonsei 
University, Seoul, Korea). The Institutional Review Board 
of Gangnam Severance Hospital approved this study in 
accordance with good clinical practice guidelines and the 
Declaration of Helsinki (3-2014-0239).
An OPTIVIEW Universal DAB kit (Ventana 
Medical Systems, Tucson, AZ, USA) was used for IHC 
staining. Slides were deparaffinized and rehydrated with 
sequential incubation in xylene, 100% to 70% ethanol, 
and distilled water. After antigen retrieval with cell 
conditioner 1 for 24 min at 100°C, slides were immersed 
with 3% H2O2 for 4 min at 37°C and probed with anti-
cIAP-2 antibodies (NB100-56132; Novus International, 
St. Charles, MO, USA) for 16 min at 37°C. OptiView 
HQ Universal Linker and OptiView HRP Multimer 
were sequentially added to the slides for 8 min each. 
Subsequently, 3,3′-diaminobenzidine (DAB) substrate 
solution was added. Slides were counterstained with 
hematoxylin and bluing reagent. Digital images of slides 
with DAB staining were obtained using Leica Application 
Suite (LAS) Microscope Software (Leica Microsystems 
Inc., Buffalo Grove, IL, USA).
IHC staining for cIAP2 was classified as negative (0), 
1+, or 2+ in high-magnification (200×) fields according to 
the intensity of cytoplasmic staining and using quantitative 
scoring methods [57]. The scoring methods used in 
this study are described in Supplementary Table 2. The 
cIAP2-positive status was assigned for scores 1+ and 2+. 
The interpretation of IHC staining was evaluated by a 
pathologist who had no information regarding the clinical 
outcomes.
Scratch wound cell migration assay (wound 
healing assay)
To generate wounds on breast cancer cells, IBIDI 
culture inserts (IBIDI, Martinsried, Germany) were placed 
into wells of 24-well plates, and cells were added into the 
two reservoirs of the inserts. Cells were plated at 1.5 × 
105 BT474 cells/well, 1.2 × 105 MCF7 cells/well, 4 × 
104 MDA-MB-231 cells/well, and 3 × 104 Hs 578T cells/
well. After incubation for 24 h in a 37°C CO2 incubator, 
the culture inserts were removed, and images of the 
wounds were taken at 0 and 24 h using an Olympus IX71 
microscope (Olympus France; Rungis, France).
For kinetic analysis, cIAP2-silenced MDA-MB-231 
cells (4 × 104 cells/well) and Hs 578T (1 × 104 cells/well) 
were seeded into a 96-well Essen ImageLock microplate 
(Essen BioScience, Ann Arbor, MI, USA) and incubated 
in a 37°C CO2 incubator for 24 h. The cell monolayer was 
scratched using a 96-well Wound Maker and then washed 
with phosphate-buffered saline (PBS) to remove the 
detached cells. Images of the wounds were automatically 
recorded at 6-h intervals for 24 h using IncuCyte ZOOM 
software.
Scratch wound cell invasion assays
cIAP2-silenced MDA-MB-231 cells (4 × 104 cells/
well) and Hs 578T cells (1 × 104 cells/well) were seeded 
into a 96-well Essen ImageLock microplate coated with 
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diluted Matrigel (100 μg/mL) in cold culture medium, and 
cells were then incubated in a 37°C CO2 incubator for 24 
h. The cells were scratched using a 96-well Wound Maker 
and then washed with PBS to remove detached cells. Next, 
50 μL diluted Matrigel (8 mg/mL) in cold culture medium 
was added to each well, and cells were incubated in a 37°C 
CO2 incubator for 30 min. When the Matrigel solution was 
solidified, 100 μL cell culture medium was added to each 
well. Images of the wounds were automatically recorded 
at 6-h intervals for 48 h using IncuCyte ZOOM software.
Reverse transcription polymerase chain reaction 
(RT-PCR) and quantitative real-time RT-PCR
RNA was extracted using TRIzol reagent 
(Invitrogen), and cDNA was synthesized using Oligo 
dT primers (Invitrogen) and SuperScript III Reverse 
Transcriptase (Invitrogen) according to the manufacturer’s 
instructions. Synthesized cDNAs were used as templates 
for subsequent PCR of BIRC1, BIRC2, BIRC3, BIRC4, 
BIRC5, BIRC6, BIRC7, BIRC8, CDH1, CDH2, EPCAM, 
VIM, ACTA2, SNAI1, SNAI2, and GAPDH genes. 
Primer sequences used in this study are described in 
Supplementary Table 3.
Quantitative real-time RT-PCR was carried 
out using a KAPA SYBR FAST qPCR kit (KaPa 
Biosystems, Wilmington, MA, USA), and amplification 
was performed on an ABI Prism 7000 detection system 
(Applied Biosystems, Waltham, MA, USA) according 
to the conditions recommended by the manufacturer. 
The experiments were performed in triplicate and 
normalized to the expression of hypoxanthine-guanine 
phosphoribosyltransferase (HPRT). The relative 
expression levels of the target genes were calculated by 
the 2−ΔΔCt method.
Statistical methods
Unpaired Student’s t-tests were used to determine 
significant differences between groups. All statistical 
analyses were performed using GraphPad Prism 6.0a 
software (GraphPad Software, La Jolla, CA, USA). Values 
represent means ± standard deviations (SDs). Differences 
with P values of less than 0.05 were considered significant.
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